Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com
Stock analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a […]
Stock analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a […]
